Bortezomib in Treating Patients With Newly Diagnosed High-Risk Stage III Multiple Myeloma - Related Studies

Bortezomib in Treating Patients With Newly Diagnosed High-Risk Stage III Multiple Myeloma

This study is ongoing, but not recruiting participants.

Study NCT00075881. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Additional conditions recognized in this trial
		Multiple Myeloma
		Neoplasms, Plasma Cell

2	More general conditions related to this trial
		Blood Protein Disorders
		Cardiovascular Diseases
		Hematologic Diseases
		Hemorrhagic Disorders
		Hemostatic Disorders
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Paraproteinemias
		Vascular Diseases

3	Interventions listed in this trial
		bortezomib

4	More general drug interventions related to this trial
		Antineoplastic Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Protease Inhibitors
		Therapeutic Uses

5	Sponsors listed in this trial
		Eastern Cooperative Oncology Group
		National Cancer Institute (NCI)